Abstract

Background The somatically related antibodies, PG9 and PG16, neutralize 70-80% of HIV-1 isolates and bind a glycosylated epitope in the V1/V2 domain of HIV-1 gp120. Mutations in V1/V2, and sometimes V3 depending on the HIV-1 strain, affect neutralization and a glycan on Asn160 is required for neutralization. Both antibodies also preferentially bind the native trimer over monomeric gp120, especially PG16. The structure of PG9 in complex with its epitope, a scaffolded V1/V2 from HIV-1 strain ZM109, was recently solved and showed that PG9 targets a site of vulnerability comprising 2 glycans and a b-strand.

Highlights

  • The somatically related antibodies, PG9 and PG16, neutralize 70-80% of HIV-1 isolates and bind a glycosylated epitope in the V1/V2 domain of HIV-1 gp120

  • Mutations in V1/V2, and sometimes V3 depending on the HIV-1 strain, affect neutralization and a glycan on Asn160 is required for neutralization

  • A stable complex could be obtained between PG16 and a scaffolded V1/V2 domain from ZM109, and this complex was crystallized

Read more

Summary

Background

The somatically related antibodies, PG9 and PG16, neutralize 70-80% of HIV-1 isolates and bind a glycosylated epitope in the V1/V2 domain of HIV-1 gp120. Mutations in V1/V2, and sometimes V3 depending on the HIV-1 strain, affect neutralization and a glycan on Asn160 is required for neutralization. Both antibodies preferentially bind the native trimer over monomeric gp120, especially PG16. The structure of PG9 in complex with its epitope, a scaffolded V1/V2 from HIV-1 strain ZM109, was recently solved and showed that PG9 targets a site of vulnerability comprising 2 glycans and a b-strand

Methods
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.